HW
SRNE

Hancock Whitney’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Hancock Whitney’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-125,000
Closed -$1.21M – 836
2021
Q2 		$1.21M Hold
125,000
– – 0.04% 371
2021
Q1 		$1.03M Sell
125,000
-382
-0.3% -$4.03K 0.04% 398
2020
Q4 		$856K Sell
125,382
-7,596
-6% -$61K 0.03% 411
2020
Q3 		$1.48M Sell
132,978
-37,262
-22% -$341K 0.05% 286
2020
Q2 		$1.07M Buy
+170,240
New +$652K 0.04% 356

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Hancock Whitney's SRNE Position: Q3 2021 in Review

Hancock Whitney sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2021, closing a stake of 125,000 shares — an estimated $1.21M sold.

Hancock Whitney first reported a position in SRNE in Q2 2020 and held it in 5 quarters. The position peaked at $1.48M in Q3 2020. 220 funds tracked by Wall St. Rank hold SRNE as of Q3 2021.

  • Hancock Whitney reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2021 after selling out during the quarter.
  • Hancock Whitney sold 125,000 Sorrento Therapeutics, Inc. shares in Q3 2021, an estimated $1.21M.
  • Hancock Whitney first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 5 quarters.
  • Hancock Whitney's Sorrento Therapeutics, Inc. position peaked at $1.48M in Q3 2020.
  • 220 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2021.

Based on Hancock Whitney's 13F filing for Q3 2021, filed 4 Nov 2021.